Article

Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A

Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
Bioorganic & Medicinal Chemistry (Impact Factor: 2.95). 02/2006; 14(2):395-408. DOI: 10.1016/j.bmc.2005.08.018
Source: PubMed

ABSTRACT Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase--the zinc-bound, catalytic domain of BoNTA--at a drug concentration of 20 microM. However, optimization of these inhibitors is hampered by challenges including the computational evaluation of the ability of a zinc ligand to compete for coordination with nearby residues in the active site of BoNTA. No improved inhibitor of the endopeptidase has been reported. This article reports the development of a serotype-selective, small-molecule inhibitor of BoNTA with a K(i) of 12 microM. This inhibitor was designed to coordinate the zinc ion embedded in the active site of the enzyme for affinity and to interact with a species-specific residue in the active site for selectivity. It is the most potent small-molecule inhibitor of BoNTA reported to date. The results suggest that multiple molecular dynamics simulations using the cationic dummy atom approach are useful to structure-based design of zinc protease inhibitors.

Full-text

Available from: Alfonso T Garcia-Sosa, Apr 19, 2015
0 Followers
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CLN025 is one of the smallest fast-folding proteins. Until now it has not been reported that CLN025 can autonomously fold to its native conformation in a classical, all-atom, and isothermal-isobaric molecular dynamics (MD) simulation. This article reports the autonomous and repeated folding of CLN025 from a fully extended backbone conformation to its native conformation in explicit solvent in multiple 500-ns MD simulations at 277 K and 1 atm with the first folding event occurring as early as 66.1 ns. These simulations were accomplished by using AMBER forcefield derivatives with atomic masses reduced by 10-fold on Apple Mac Pros. By contrast, no folding event was observed when the simulations were repeated using the original AMBER forcefields of FF12SB and FF14SB. The results demonstrate that low-mass MD simulation is a simple and generic technique to enhance configurational sampling. This technique may propel autonomous folding of a wide range of miniature proteins in classical, all-atom, and isothermal-isobaric MD simulations performed on commodity computers—an important step forward in quantitative biology.
    Biochemical and Biophysical Research Communications 09/2014; 452(3). DOI:10.1016/j.bbrc.2014.08.119 · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have successfully developed a Au-catalyzed annulation method to produce substituted 3-arylindoles from the reaction of nitrosoarenes with arylsubstituted acetylenes under reductive conditions using sodium borohydride. Terminal alkynes reacted better than non-terminal ones with various substituted nitrosoarenes to afford regioselective 3-substituted indoles. This method is simple and straightforward and can be applied successfully to the synthesis of highly substituted indoles.
    ACS Catalysis 12/2010; 1(1):29–31. DOI:10.1021/cs100024n · 7.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In seiner klassischen Erzählung “Der Seltsame Fall des Dr. Jekyll und Mr. Hide” beschreibt Robert Louis Stevenson einen gespaltenen Menschen zwischen Gut und Böse. Botulinum-Neurotoxin (BoNT), der wirksamste bekannte Giftstoff, ist von ähnlich zwiespältiger Natur: BoNT zeigt einerseits eine ausgeprägte Morbidität und Mortalität, kommt andererseits aber – wenn auch in viel geringeren Dosen – in einem breiten Spektrum klinischer Szenarien zum Einsatz. In jüngerer Zeit sind enorme Fortschritte beim Verständnis der Struktur und Funktion von BoNT erzielt worden, die eine intensive Erforschung von biomakromolekularen und niedermolekularen Modulatoren der BoNT-Aktivität nach sich zogen. Ein Schwerpunkt dieser Projekte lag auf der Identifizierung von Inhibitoren, die einer BoNT-Exposition, z. B. im Falle eines bioterroristischen Anschlags, entgegenwirken können. Dieser Aufsatz fasst die aktuellen Fortschritte bei der Entwicklung von Therapeutika zur Prävention und Behandlung von Botulismus zusammen, mit einem Schwerpunkt auf Impfstoffen sowie peptidischen und niedermolekularen Inhibitoren.
    Angewandte Chemie 10/2008; 120(44). DOI:10.1002/ange.200705531